McCredie K B, Bodey G P, Freireich E J, Hester J P, Rodriguez V, Keating M J
Cancer. 1981 Mar 15;47(6):1256-61. doi: 10.1002/1097-0142(19810315)47:6<1256::aid-cncr2820470605>3.0.co;2-9.
Sixty-two adult patients with acute myeloid leukemia were treated with a chemotherapy program of Adriamycin, Cytosine Arabinoside (Ara-C), vincristine, and prednisone (Ad-OAP). Immunotherapy with BCG by scarification was administered before and/or during remission induction therapy. Maintenance chemoimmunotherapy consisted of Ara-C, vincristine, prednisone, and BCG. Patients still in remission after 12 months received late intensification chemotherapy for three courses before discontinuing chemotherapy. Forty-four (71%) patients achieved a complete remission (CR). The CR rate for patients less than 50 years of age ws 84% (32/38). Age was strongly predictive for response and survival. An additional 14 patients with acute lymphoid leukemia were treated with the same program; ten patients responded, all have relapsed and died. Nine patients with AML remain alive 4 1/2-6+ years from diagnosis.
62例成年急性髓细胞白血病患者接受了阿霉素、阿糖胞苷（Ara-C）、长春新碱和泼尼松（Ad-OAP）的化疗方案治疗。在缓解诱导治疗前和/或期间，通过划痕法给予卡介苗免疫治疗。维持化学免疫治疗包括阿糖胞苷、长春新碱、泼尼松和卡介苗。12个月后仍处于缓解期的患者在停止化疗前接受了三个疗程的晚期强化化疗。44例（71%）患者达到完全缓解（CR）。年龄小于50岁患者的CR率为84%（32/38）。年龄是反应和生存的强烈预测因素。另外14例急性淋巴细胞白血病患者接受了相同方案治疗；10例患者有反应，但均复发并死亡。9例急性髓细胞白血病患者自诊断起存活4.5至6年以上。
